KLP Kapitalforvaltning AS bought a new stake in Embecta Corp. (NASDAQ:EMBC – Free Report) during the 4th quarter, according ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Mizuho initiated coverage of Embecta (EMBC) with a Neutral rating and $15 price target The firm says its rating balances the company’s ...

Shares of Embecta stock opened at $12.30 on Wednesday. The firm’s 50 day simple moving average is $13.73 and its two-hundred day simple moving average is $15.98. The firm has a market ...

Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago. These ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

The publication, entitled “Advance Insulin Injection Technique and Education with FITTER Forward Expert Recommendations,” is available in Mayo Clinic Proceedings ’ April print edition and online here ...

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application.

embecta leveraged World Diabetes Day for the launch of its All In campaign to establish itself as a pure player in diabetes management, foster access to diabetes education for healthcare professionals ...

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business Becton Dickinson plans to spin off its Biosciences and ...

PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...